Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib – Single Centre Experience

1. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960; 132: 1497.Search in Google Scholar

2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogeneus leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290-293.10.1038/243290a0Search in Google Scholar

3. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph’ translocation. Nature. 1985; 315: 758-761.10.1038/315758a0Search in Google Scholar

4. Collins SJ, Kubonishi I, Miyoshi I, Groudine M. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science. 1984; 225: 72-74.10.1126/science.6587568Search in Google Scholar

5. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.10.1038/nm0596-561Search in Google Scholar

6. Goldman JM, Melo JV. Chronic Myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15): 1451-64.10.1056/NEJMra020777Search in Google Scholar

7. Hughes TP, Kaeda J, Branford S, Rudzi Z, Hochhaus A, Hensly ML, et al. Frequency of major molecular response to imatinib or intereferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003; 349(15): 1423-32.10.1056/NEJMoa030513Search in Google Scholar

8. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International Randomized study of Interferon versus STI571 (IRIS) 7- year follow-up: sustained survival, low rate of transformation and increase rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood. 2008; 112: Abstract 186.10.1182/blood.V112.11.186.186Search in Google Scholar

9. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperly JF, et al. European Leukemia Net recommendations for management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-884.10.1182/blood-2013-05-501569Search in Google Scholar

10. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11): 1018-1029.10.1016/S1470-2045(07)70342-XSearch in Google Scholar

11. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(12): 1116-1128.10.1016/S1470-2045(07)70379-0Search in Google Scholar

12. Soverini S, Hochhaus A, Nicolini FE, et al. BCRABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemia Net. Blood. 2011; 118(5): 1208-1215.10.1182/blood-2010-12-32640521562040Search in Google Scholar

13. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101(10): 3794-3800.10.1182/blood-2002-09-279012560227Search in Google Scholar

14. Deininger MWN, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007; 110(7): 1509-1519.10.1002/cncr.2293617702093Search in Google Scholar

15. Lee SE, Choi SY, Bang JH, et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012; 205(11): 563-571.10.1016/j.cancergen.2012.09.00323111092Search in Google Scholar

16. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, et al. Five-year follow-up of patient receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-17.10.1056/NEJMoa06286717151364Search in Google Scholar

17. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained response in an intention-to treat analysis. J Clin Oncol. 2008; 26(20): 3358-63.10.1200/JCO.2007.15.815418519952Search in Google Scholar

18. Hehlmann R, Lauseker M, Junk-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011; 29(12): 1634-42.10.1200/JCO.2010.32.059821422420Search in Google Scholar

19. Cortes JE, Kantarjian HM, Goldberg SL, et al. Highdose imatinib in newly diagnosed chronic myeloid leukemia: high rates of rapid cytogenetic and molecular response. J Clin Oncol. 2009; 27(28): 4754-9.10.1200/JCO.2008.20.3869497920019720924Search in Google Scholar